{"id":"NCT03825380","sponsor":"Laboratoires Thea","briefTitle":"Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients","officialTitle":"Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-11-23","primaryCompletion":"2021-02-03","completion":"2021-02-24","firstPosted":"2019-01-31","resultsPosted":"2023-11-21","lastUpdate":"2023-11-21"},"enrollment":485,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Ocular Hypertension","Glaucoma"],"interventions":[{"type":"DRUG","name":"Bimatoprost","otherNames":[]},{"type":"DRUG","name":"Lumigan®","otherNames":[]}],"arms":[{"label":"T4032","type":"EXPERIMENTAL"},{"label":"Lumigan®","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess the efficacy and safety of T4032 versus Lumigan.","primaryOutcome":{"measure":"Intra-Ocular Pressure","timeFrame":"Week 12","effectByArm":[{"arm":"T4032","deltaMin":-9.67,"sd":0.19},{"arm":"Lumigan®","deltaMin":-9.5,"sd":0.18}],"pValues":[{"comp":"OG000 vs OG001","p":"0.453"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":1,"countries":["Estonia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":236},"commonTop":["Conjunctival hyperaemia"]}}